Ning Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ning Liu has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Kelvin Kar-Wing Chan
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Canadian Center for Applied Research in Cancer Control, Toronto, Ontario, Canada; ICES, Toronto, Ontario, Canada; Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Canada
4 shared publications - Monika K. Krzyzanowska
Division of Medical Oncology and Hematology, University Health Network—Princess Margaret Cancer Center, Toronto, Canada
4 shared publications - Rinku Sutradhar
ICES, Toronto, ON M4N 3M5, Canada
4 shared publications - Craig C. Earle
Department of Medicine, University of Toronto, Toronto, ON, Canada
3 shared publications - Lee Mozessohn
Odette Cancer Centre, Toronto, Ontario, Canada
3 shared publications - Maria C. Cusimano
Department of Obstetrics & Gynecology, University of Toronto, Toronto, ON, Canada
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma
Background: Opioid exposure during cancer treatment is common and leads to new persistent opioid use (NPOU) in a subset of patients. There are limited data on the incidence and predictors of NPOU among patients with diffuse large B-cell lymphoma (DLBCL). Methods: We conducted a population-based cohort study including patients with DLBCL ≥18 years old from Ontario, Canada who received first-line rituximab-based chemoimmunotherapy from 2014 to 2021 and survived >365 days after treatment. We defined opioid exposure as filling ≥1 opioid prescriptions between 90 days prior to and 180 days after first chemoimmunotherapy (index date). The primary outcome was NPOU defined as filling ≥1 opioid prescriptions within both 181-360 days and 361-545 days after index. We used a multivariable modified Poisson regression model to assess the relative risk (RR) of NPOU. Results: Our cohort consisted of 4988 patients with DLBCL with a median age of 66 years. Opioid exposure occurred in 55.0% of patients. 6.7% of patients fulfilled criteria for NPOU, including 10.4% of exposed patients compared to 2.4% of unexposed patients. In the multivariable analysis, exposed patients were 4 times more likely to develop NPOU (RR 3.79, 95% CI = 2.85 to 5.06). Other predictors of NPOU included relapsed/refractory disease, palliative care utilization, prior mental health diagnoses, and high-dose vs low-dose opioid exposure. Conclusions: More than 1 in 2 DLBCL patients were exposed to opioids during treatment and 1 in 10 exposed patients developed NPOU. Our study identified several predictors of NPOU in DLBCL, which may enable clinicians to identify high-risk patients who would benefit from early intervention.
- 1 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessEvaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma
Background: Opioid exposure during cancer treatment is common and leads to new persistent opioid use (NPOU) in a subset of patients. There are limited data on the incidence and predictors of NPOU among patients with diffuse large B-cell lymphoma (DLBCL). Methods: We conducted a population-based cohort study including patients with DLBCL ≥18 years old from Ontario, Canada who received first-line rituximab-based chemoimmunotherapy from 2014 to 2021 and survived >365 days after treatment. We defined opioid exposure as filling ≥1 opioid prescriptions between 90 days prior to and 180 days after first chemoimmunotherapy (index date). The primary outcome was NPOU defined as filling ≥1 opioid prescriptions within both 181-360 days and 361-545 days after index. We used a multivariable modified Poisson regression model to assess the relative risk (RR) of NPOU. Results: Our cohort consisted of 4988 patients with DLBCL with a median age of 66 years. Opioid exposure occurred in 55.0% of patients. 6.7% of patients fulfilled criteria for NPOU, including 10.4% of exposed patients compared to 2.4% of unexposed patients. In the multivariable analysis, exposed patients were 4 times more likely to develop NPOU (RR 3.79, 95% CI = 2.85 to 5.06). Other predictors of NPOU included relapsed/refractory disease, palliative care utilization, prior mental health diagnoses, and high-dose vs low-dose opioid exposure. Conclusions: More than 1 in 2 DLBCL patients were exposed to opioids during treatment and 1 in 10 exposed patients developed NPOU. Our study identified several predictors of NPOU in DLBCL, which may enable clinicians to identify high-risk patients who would benefit from early intervention.
- Open Access
- 4 July 2026
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 235 (5) , 1081-1092
Association of surgical approach with oncologic outcomes in low-risk cervical cancer
- 4 July 2026
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 235 (5) , 1081-1092
Open AccessAssociation of surgical approach with oncologic outcomes in low-risk cervical cancer
- 8 April 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (4)
Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study
Background & Aims: Individuals with inflammatory bowel disease (IBD) may have worse obstetrical outcomes than those without IBD. We assessed the odds of severe maternal morbidity (SMM) among individuals with IBD compared to those without by IBD subtype (Crohn’s disease [CD] or ulcerative colitis [UC]), and whether the method of delivery impacted the odds of SMM. Methods: We conducted a retrospective, population-based matched cohort study of females aged 15-49 years in Ontario, Canada from 2003 to 2019 delivering at 20+ weeks’ gestation. The primary outcome was SMM occurring between 20 weeks’ gestation up to 42-days postpartum. We identified deliveries among individuals with IBD using health administrative data and matched them 1:5 to deliveries among individuals without IBD from the general population of Ontario residents. Multivariable regression models estimated the adjusted odds ratio (OR) of SMM in antepartum and postpartum periods. We tested for interactions between IBD status and delivery method. Results: 6833 deliveries in individuals with IBD (3800 CD and 3033 UC) were matched to 34 165 non-IBD deliveries. More individuals with IBD underwent C-section (36.5% vs 30.9%, standardized mean difference, SMD: 0.12). Compared with individuals without IBD, those with IBD had higher odds of antepartum SMM (OR: 3.5, 95% CI: 2.1-5.8) and postpartum SMM (OR: 1.3, 95% CI: 1.0-1.5). The odds of SMM among individuals with and without IBD was not modified by method of delivery (interaction term P = .17). Conclusions: Individuals with IBD were at increased risk of SMM, independent of delivery method. Pregnancy care should focus on optimization of other IBD-related risk factors.
- 8 April 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (4)
Assessing the impact of delivery method on severe maternal morbidity among individuals with inflammatory bowel disease: a population-based study
Background & Aims: Individuals with inflammatory bowel disease (IBD) may have worse obstetrical outcomes than those without IBD. We assessed the odds of severe maternal morbidity (SMM) among individuals with IBD compared to those without by IBD subtype (Crohn’s disease [CD] or ulcerative colitis [UC]), and whether the method of delivery impacted the odds of SMM. Methods: We conducted a retrospective, population-based matched cohort study of females aged 15-49 years in Ontario, Canada from 2003 to 2019 delivering at 20+ weeks’ gestation. The primary outcome was SMM occurring between 20 weeks’ gestation up to 42-days postpartum. We identified deliveries among individuals with IBD using health administrative data and matched them 1:5 to deliveries among individuals without IBD from the general population of Ontario residents. Multivariable regression models estimated the adjusted odds ratio (OR) of SMM in antepartum and postpartum periods. We tested for interactions between IBD status and delivery method. Results: 6833 deliveries in individuals with IBD (3800 CD and 3033 UC) were matched to 34 165 non-IBD deliveries. More individuals with IBD underwent C-section (36.5% vs 30.9%, standardized mean difference, SMD: 0.12). Compared with individuals without IBD, those with IBD had higher odds of antepartum SMM (OR: 3.5, 95% CI: 2.1-5.8) and postpartum SMM (OR: 1.3, 95% CI: 1.0-1.5). The odds of SMM among individuals with and without IBD was not modified by method of delivery (interaction term P = .17). Conclusions: Individuals with IBD were at increased risk of SMM, independent of delivery method. Pregnancy care should focus on optimization of other IBD-related risk factors.
- Open Access
- 30 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2304-2313
Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed/refractory large B-cell lymphoma (R/R-LBCL) after 2 lines of systemic therapy since late 2019. Real-world outcome data have been limited by lack of comparison to historical care. Using propensity-weighted analysis, we compared 3-year survival, health care resource use (HRU), and hospitalization events for patients with R/R-LBCL treated with CAR-T (n = 85) vs historical controls (HCs) treated before CAR-T approval who would have been eligible based on present criteria (n = 150). CAR-T 3-year overall survival (OS) was 59% (95% confidence interval [CI], 42-72; median, not reached) vs 10% (95% CI, 5-16; median, 4.4 months) in HCs. Three-year CAR-T progression-free survival (PFS) was 48% (95% CI, 32-63]; median, 14.4 months) vs 6% (95% CI, 3-11; median, 3.6 months) in HCs. The hazard ratio (HR) for OS was 0.21 (95% CI, 0.14-0.31), and for PFS was 0.28 (95% CI, 0.2-0.39), comparing CAR-T vs HCs. Per 1000 person-days at risk, patients receiving CAR-T had fewer hospital admissions than HCs (5.32 vs 9.1), emergency visits (2.33 vs 4.81), and intensive care admissions (0.53 vs 1.25), plus lower hospitalization rates for fever (0.93 vs 1.63), infection (1.48 vs 3.08), and neutropenia (0.66 vs 1.97; all P< .001). CAR-T produced a sustained survival benefit, and, despite well-described CAR-T toxicities, HCs experienced more hospitalization events, underscoring the lack of effective salvage treatments. As one of the largest real-world comparisons of patients with R/R-LBCL receiving CAR-T vs previous standard of care, this study demonstrated its improved effectiveness and reduced HRU.
- 30 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (7) , 2304-2313
Open AccessImproved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed/refractory large B-cell lymphoma (R/R-LBCL) after 2 lines of systemic therapy since late 2019. Real-world outcome data have been limited by lack of comparison to historical care. Using propensity-weighted analysis, we compared 3-year survival, health care resource use (HRU), and hospitalization events for patients with R/R-LBCL treated with CAR-T (n = 85) vs historical controls (HCs) treated before CAR-T approval who would have been eligible based on present criteria (n = 150). CAR-T 3-year overall survival (OS) was 59% (95% confidence interval [CI], 42-72; median, not reached) vs 10% (95% CI, 5-16; median, 4.4 months) in HCs. Three-year CAR-T progression-free survival (PFS) was 48% (95% CI, 32-63]; median, 14.4 months) vs 6% (95% CI, 3-11; median, 3.6 months) in HCs. The hazard ratio (HR) for OS was 0.21 (95% CI, 0.14-0.31), and for PFS was 0.28 (95% CI, 0.2-0.39), comparing CAR-T vs HCs. Per 1000 person-days at risk, patients receiving CAR-T had fewer hospital admissions than HCs (5.32 vs 9.1), emergency visits (2.33 vs 4.81), and intensive care admissions (0.53 vs 1.25), plus lower hospitalization rates for fever (0.93 vs 1.63), infection (1.48 vs 3.08), and neutropenia (0.66 vs 1.97; all P< .001). CAR-T produced a sustained survival benefit, and, despite well-described CAR-T toxicities, HCs experienced more hospitalization events, underscoring the lack of effective salvage treatments. As one of the largest real-world comparisons of patients with R/R-LBCL receiving CAR-T vs previous standard of care, this study demonstrated its improved effectiveness and reduced HRU.
- 26 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (5) , 892-902
Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment
Background: Older and medically frail adults are underrepresented in clinical trials evaluating immune checkpoint inhibitors, leading to a knowledge gap on their risk of acute care use and immune-related adverse events. We performed a population-level study to evaluate the impact of age and frailty among older adults receiving immune checkpoint inhibitors on acute care use and immune-related adverse events–related hospitalizations. Methods: Patients with cancer aged 65 years or older who initiated therapy with immune checkpoint inhibitors between June 2012 and October 2018 (Ontario, Canada) were identified using systemic therapy administration data. The cohort was linked to other databases to obtain covariates and outcomes. Multivariable Cox proportional models evaluated the impact of age and frailty on acute care use and hospitalization for immune-related adverse events. Results: Among 2737 patients, the median age was 73 years; 26% were prefrail, and 4% were frail; 72% required acute care use, whereas 8% had an immune-related adverse event–related hospitalization. Increasing frailty was associated with increased risk of acute care use (prefrail vs robust, adjusted hazard ratio [HR] = 1.20, 95% confidence interval [CI] = 1.07 to 1.36, P = .003; frail vs robust, adjusted HR = 1.45, 95% CI = 1.12 to 1.86, P = .004), but age was not associated with acute care use. Increasing age was associated with reduced risk of hospitalization for immune-related adverse events (adjusted HR = 0.97 per year, 95% CI = 0.95 to 0.99, P = .01); compared with patients aged 65-69 years, patients 80 years of age or older had reduced risk of hospitalization for immune-related adverse events (adjusted HR = 0.63, 95% CI = 0.39 to 1.01, P = .05). Frailty was not associated with immune-related adverse event–related hospitalizations. Associations remained consistent when evaluating age and frailty in the same models. Conclusions: Age was associated with reduced risk of hospitalization for immune-related adverse events but not acute care use, whereas increasing frailty was associated acute care use but not immune-related adverse event–related hospitalization. Age and frailty may need to be considered independently when evaluating their impact on toxicity among older adults receiving immune checkpoint inhibitors.
- 26 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (5) , 892-902
Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment
Background: Older and medically frail adults are underrepresented in clinical trials evaluating immune checkpoint inhibitors, leading to a knowledge gap on their risk of acute care use and immune-related adverse events. We performed a population-level study to evaluate the impact of age and frailty among older adults receiving immune checkpoint inhibitors on acute care use and immune-related adverse events–related hospitalizations. Methods: Patients with cancer aged 65 years or older who initiated therapy with immune checkpoint inhibitors between June 2012 and October 2018 (Ontario, Canada) were identified using systemic therapy administration data. The cohort was linked to other databases to obtain covariates and outcomes. Multivariable Cox proportional models evaluated the impact of age and frailty on acute care use and hospitalization for immune-related adverse events. Results: Among 2737 patients, the median age was 73 years; 26% were prefrail, and 4% were frail; 72% required acute care use, whereas 8% had an immune-related adverse event–related hospitalization. Increasing frailty was associated with increased risk of acute care use (prefrail vs robust, adjusted hazard ratio [HR] = 1.20, 95% confidence interval [CI] = 1.07 to 1.36, P = .003; frail vs robust, adjusted HR = 1.45, 95% CI = 1.12 to 1.86, P = .004), but age was not associated with acute care use. Increasing age was associated with reduced risk of hospitalization for immune-related adverse events (adjusted HR = 0.97 per year, 95% CI = 0.95 to 0.99, P = .01); compared with patients aged 65-69 years, patients 80 years of age or older had reduced risk of hospitalization for immune-related adverse events (adjusted HR = 0.63, 95% CI = 0.39 to 1.01, P = .05). Frailty was not associated with immune-related adverse event–related hospitalizations. Associations remained consistent when evaluating age and frailty in the same models. Conclusions: Age was associated with reduced risk of hospitalization for immune-related adverse events but not acute care use, whereas increasing frailty was associated acute care use but not immune-related adverse event–related hospitalization. Age and frailty may need to be considered independently when evaluating their impact on toxicity among older adults receiving immune checkpoint inhibitors.
- Open Access
- 20 November 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100184
Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario
- 20 November 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (2) , 100184
Open AccessOutcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Development of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Open AccessDevelopment of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- Open Access
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100117
Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100117
Open AccessOutcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis
- Open Access
- 30 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (17) , 4625-4632
Health care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
Half of older patients with diffuse large B-cell lymphoma (DLBCL) receiving curative-intent treatment are frail. Understanding the differences in health care utilization including costs between frail and nonfrail patients can inform appropriate models of care. A retrospective cohort study was conducted using population-based data in Ontario, Canada. Patients aged ≥66 years with DLBCL who received frontline curative-intent chemoimmunotherapy between 2006 and 2017 were included. Frailty was defined using a cumulative deficit–based frailty index. Health care utilization and costs were grouped into 5 phases: (1) 90 days preceding first treatment; (2) early treatment (0 to +90 days after starting treatment); (3) late treatment (+91 to +180 days); (4) follow-up (+181 to –181 days before death); and (5) end of life (last 180 days before death). Costs were standardized to 30-day intervals (2019 Canadian dollars). A total of 5527 patients were included (median age, 75 years; 48% female). A total of 2699 patients (49%) were classified as frail. The median costs for frail vs nonfrail patients per 30 days based on phase of care were (1) $5683 vs $2586 ; (2) $13 090 vs $11 256; (3) $5734 vs $4883; (4) $1138 vs $686; and (5) $11 413 vs $9089; statistically significant in all phases. In multivariable modeling, frail patients had higher rates of emergency department visits and hospitalizations and increased costs than nonfrail patients through all phases except end-of-life phase. During end-of-life phase, a substantial portion of patients (n = 2569 [84%]) required admission to hospital; 684 (27%) required intensive care unit admission. Future work could assess whether certain hospitalizations are preventable, particularly for patients identified as frail.
- 30 August 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (17) , 4625-4632
Open AccessHealth care utilization and costs for frail vs nonfrail patients with diffuse large B-cell lymphoma
Half of older patients with diffuse large B-cell lymphoma (DLBCL) receiving curative-intent treatment are frail. Understanding the differences in health care utilization including costs between frail and nonfrail patients can inform appropriate models of care. A retrospective cohort study was conducted using population-based data in Ontario, Canada. Patients aged ≥66 years with DLBCL who received frontline curative-intent chemoimmunotherapy between 2006 and 2017 were included. Frailty was defined using a cumulative deficit–based frailty index. Health care utilization and costs were grouped into 5 phases: (1) 90 days preceding first treatment; (2) early treatment (0 to +90 days after starting treatment); (3) late treatment (+91 to +180 days); (4) follow-up (+181 to –181 days before death); and (5) end of life (last 180 days before death). Costs were standardized to 30-day intervals (2019 Canadian dollars). A total of 5527 patients were included (median age, 75 years; 48% female). A total of 2699 patients (49%) were classified as frail. The median costs for frail vs nonfrail patients per 30 days based on phase of care were (1) $5683 vs $2586 ; (2) $13 090 vs $11 256; (3) $5734 vs $4883; (4) $1138 vs $686; and (5) $11 413 vs $9089; statistically significant in all phases. In multivariable modeling, frail patients had higher rates of emergency department visits and hospitalizations and increased costs than nonfrail patients through all phases except end-of-life phase. During end-of-life phase, a substantial portion of patients (n = 2569 [84%]) required admission to hospital; 684 (27%) required intensive care unit admission. Future work could assess whether certain hospitalizations are preventable, particularly for patients identified as frail.
- Open Access
- 29 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1424385
TUFM in health and disease: exploring its multifaceted roles
The nuclear-encoded mitochondrial protein Tu translation elongation factor, mitochondrial (TUFM) is well-known for its role in mitochondrial protein translation. Originally discovered in yeast, TUFM demonstrates significant evolutionary conservation from prokaryotes to eukaryotes. Dysregulation of TUFM has been associated with mitochondrial disorders. Although early hypothesis suggests that TUFM is localized within mitochondria, recent studies identify its presence in the cytoplasm, with this subcellular distribution being linked to distinct functions of TUFM. Significantly, in addition to its established function in mitochondrial protein quality control, recent research indicates a broader involvement of TUFM in the regulation of programmed cell death processes (e.g., autophagy, apoptosis, necroptosis, and pyroptosis) and its diverse roles in viral infection, cancer, and other disease conditions. This review seeks to offer a current summary of TUFM’s biological functions and its complex regulatory mechanisms in human health and disease. Insight into these intricate pathways controlled by TUFM may lead to the potential development of targeted therapies for a range of human diseases.
- 29 May 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1424385
Open AccessTUFM in health and disease: exploring its multifaceted roles
The nuclear-encoded mitochondrial protein Tu translation elongation factor, mitochondrial (TUFM) is well-known for its role in mitochondrial protein translation. Originally discovered in yeast, TUFM demonstrates significant evolutionary conservation from prokaryotes to eukaryotes. Dysregulation of TUFM has been associated with mitochondrial disorders. Although early hypothesis suggests that TUFM is localized within mitochondria, recent studies identify its presence in the cytoplasm, with this subcellular distribution being linked to distinct functions of TUFM. Significantly, in addition to its established function in mitochondrial protein quality control, recent research indicates a broader involvement of TUFM in the regulation of programmed cell death processes (e.g., autophagy, apoptosis, necroptosis, and pyroptosis) and its diverse roles in viral infection, cancer, and other disease conditions. This review seeks to offer a current summary of TUFM’s biological functions and its complex regulatory mechanisms in human health and disease. Insight into these intricate pathways controlled by TUFM may lead to the potential development of targeted therapies for a range of human diseases.